Galena Biopharma Pipeline Developments Third Quarter 2016 Results and Outlook
Galena Biopharma (NASDAQ:GALE), the biotechnology company focused on treating blood diseases and cancer, are looked at by Traders News Source, an equity research firm specializing in small and micro-cap securities, to see whether they can recover further lost ground after a rough 2016. They announced earnings for the third quarter of 2016 on November 9, …
Galena Biopharma (NASDAQ:GALE), the biotechnology company focused on treating blood diseases and cancer, are looked at by Traders News Source, an equity research firm specializing in small and micro-cap securities, to see whether they can recover further lost ground after a rough 2016. They announced earnings for the third quarter of 2016 on November 9, 2016 and shares spiked recently on a positive regulatory development.
As quoted in the press release:
Its most advanced drug is GALE-401. GALE-401 has the potential for treating the rare blood disease essential thrombocythemia (“ET”). Regarding its blood disease drug GALE-401, the addressable market is small, but there also appears to be no visible competition. Roughly 150,000 people are diagnosed with thrombocytosis, most of whom are treated.